期刊文献+

替吉奥治疗晚期胃癌临床观察 被引量:7

The Clinical Observation of S-1 Capsule in the Treatment of Advanced Gastric Cancer
下载PDF
导出
摘要 目的观察替吉奥治疗晚期胃癌的近期疗效及毒副反应。方法对20例具有可测量指标的晚期胃癌患者采用替吉奥胶囊治疗:替吉奥胶囊80 mg.m-2.d-1,分2次口服,连服14 d,21 d为1周期,连用3周期,休息1个月评价疗效及毒副反应。结果 20例患者中,CR 1例,PR 8例,SD 8例,PD 3例,总有效率45%。主要毒副反应为厌食、恶心、呕吐、皮肤色素沉着、白细胞减少等。结论替吉奥治疗晚期胃癌具有较好疗效,毒副反应轻,特别适宜于年老体弱患者。 Objective To observe the therapeutic effect and toxicities of S-1 capsule in the treatment of advanced gastric cancer. Methods All the 20 cases of advanced gastric cancer with measurable indicators received S-1 capsule treatment: S-1 capsule 80 mg·m-2·d-1,oral,2 times a day for 14 days,21 days were 1 cycle,3 cycles of chemotherapy were given,the therapeutic effect and toxicities were evaluated 1 month after chemotherapy. Results In the 20 cases,CR 1 case,PR 8 cases,SD 8 cases,PD 3 cases,the effective rate was 45%.The major toxicities were anorexia,nausea,vomiting,skin pigmentation and leucopenia. Conclusion S-1 capsule is very effective in the treatment of elderly or frail patients with advanced gastric cancer,and the toxicities can be tolerated.
作者 李岚
出处 《肿瘤基础与临床》 2012年第1期24-25,共2页 journal of basic and clinical oncology
关键词 替吉奥 晚期胃癌 疗效 S-1 capsule advanced gastric cancer therapeutic effect
  • 相关文献

参考文献3

  • 1Sakata Y,Ohtsu A,Horikoshi N,et al. Late phase I1 study of novel oral fluoropyrimidine anticancer drug S-1 ( 1 M tegafur-0.4 M gimestat-1 M 0tastat potassium) in advanced gastric cancer patients [J]. Eur J Cancer, 1998,34( 11 ) :1715-1720.
  • 2张煜,马力文.S-1在胃癌中的研究进展[J].癌症进展,2010,8(2):148-150. 被引量:18
  • 3Shirasaka T, Tsukuda M, Inuyama Y, et al. New oral anticancer drug,TS-1 (S-l)--from bench to clinic [J]. Gan To Kagaku Ryoho,2001,28(6) :855 -864.

二级参考文献19

  • 1Shirasaka T, Shimamoto Y, Ohshima H, et al. Development of a novel form of an oral 5-fluorouracil derivative ( S- 1 ) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators [ J ]. Anticancer Drugs, 1996, 7 : 548.
  • 2Takeharu Y, Shigemi M, Satoshi T, et al. Safety evaluation of oral fluoropyrimidine S-1 for short-and long-term delivery in advanced gastric cancer: Analysis of 3 758 patients [J]. Cancer Chemother Pharmaeol, 2008, 61:335.
  • 3Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1 , a novel oral derivative of 5-fluorouracil, in advanced gastric cancer [J]. Oncology, 2000, 58 : 191.
  • 4Sakata Y, Ohtsu A, Horikoshi N, et al. Late Phase Ⅱ study of novel oral fluoropyrimidine anticancer drug S-1 ( 1M tegafur-0. 4M otastat potassium) in advanced gastric cancer patients [J]. EUR J Cancer, 1998, 34 : 1715.
  • 5Koizumi W, Tanabe S, Saigenji K, et al. Phase Ⅰ/Ⅱ study of S-1 combined with cisplatin in patients with advanced gastric [J]. Br J Cancer, 2003, 8:2207.
  • 6Ajani JA, Lee FC, Singh DA, et al. Multicenter phase Ⅱ trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma [J]. J Clin Oncol, 2006, 24 : 663.
  • 7Jae-Lyun L, Hye JK, Yoon-Kook, et al. Phase Ⅰ/Ⅱ study of 3-week combination of S-1 and Cisplatin chemotherapy for metastatic or recurrent gastric cancer [ J ]. Cancer Chemother Pharmacol, 2008, 61 : 837.
  • 8Inokuchi M, Yamashita T, Yamada H, et al. Phase Ⅰ/Ⅱ study of S-1 combined with irinotecan for metastatic advanced gastric cancer [J]. Br J Cancer, 2006, 94 : 1130.
  • 9Yamaguchi K, Shimamura T, Hyodo I, et al. Phase Ⅰ/Ⅱ study of docetaxel and S-1 in patients with advanced gastric cancer [J]. Br J Cancer, 2006, 94:1803.
  • 10Mochiki E, Ohno T, amiyama Y, et al. Phase Ⅰ/Ⅱ study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer [ J ]. Br J Cancer, 2006, 95 : 1642.

共引文献17

同被引文献54

引证文献7

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部